Loading
Tagraxofusp is a fusion of the growth factor IL-3 with a bacterial toxin that homes to CD123 on a rare, aggressive blood cancer.
Approved 2018 for blastic plasmacytoid dendritic cell neoplasm (BPDCN), the first CD123-directed therapy (CR/CRc 57% in untreated patients). Capillary leak syndrome is the boxed warning. Under study in CD123+ AML and CMML, usually in combination. Now joined in BPDCN by the CD123 ADC pivekimab sunirine (2026).
IL-3 domain binds CD123 (IL-3Rα); internalised diphtheria toxin fragment inhibits protein synthesis (ADP-ribosylation of EF-2). Connects to CD123.
1.IL-3 moiety binds CD123 on the blast
Source: US prescribing information (DailyMed). Doses are for orientation; the current label governs.
Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. First cycle given inpatient for capillary leak syndrome monitoring (Part A).
Covered under the medical benefit with prior authorisation confirming diagnosis, biomarker status and line of therapy; site-of-care policies may steer infusions away from hospital outpatient departments.
20% Part B coinsurance on a high-cost infusion adds up quickly: Medigap Plan G or N, Medicare Advantage maximum out-of-pocket, Medicaid dual eligibility, or a charity fund are the usual buffers.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.
Sources: NICE TA782. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| US | 2018 | Blastic plasmacytoid dendritic cell neoplasm, adults and children ≥2 |
| Adverse event | Any grade | Grade 3+ |
|---|---|---|
| Capillary leak syndrome | 55% | 9% |
| Hypoalbuminaemia | 51% | - |
| Transaminase elevation | 60% | - |
Boxed warning. Rates read from the US prescribing information. Blank cells mean the figure was not sourced, not that it is zero.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Tagraxofusp" OR ABSTRACT:"Tagraxofusp" OR TITLE:"Elzonris" OR ABSTRACT:"Elzonris") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Tagraxofusp, not a curated reading list.
Shares CD123, Blastic plasmacytoid dendritic cell neoplasm (BPDCN), Acute myeloid leukaemia.
Shares CD123, Acute myeloid leukaemia.
Shares CD123, Monoclonal antibodies.
Shares Blastic plasmacytoid dendritic cell neoplasm (BPDCN), Acute myeloid leukaemia.